Shyra gardai
CSO EpiBiologics
Seminars
Thursday 12th March 2026
Presenting the Journey to the Clinic for a Novel Bispecific Antibody EpiTAC that Selectively Degrades EGFR in Tumours
11:50 am
- EPI-326 is a bispecific EGFR EpiTAC that drives targeted degradation of mutant and wild type EGFR specifically within tumours
- Highlighting deep and durable efficacy, favourable safety and PK, and path to IND and clinic for EPI-326
- Demonstrating preclinical advancements with in vivo data on additional programs, emphasising catalytic degrader mechanisms and tissue-specific delivery
- Exploring the transformative potential of bispecific antibody degraders for oncology and inflammatory diseases
Thursday 12th March 2026
Chair’s Opening Remarks
8:45 am
Thursday 12th March 2026
Chair’s Closing Remarks
4:20 pm
